These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 25969547)
21. Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry. La Manna A; Miccichè E; D'Agosta G; Tensol Rodrigues Pereira G; Attizzani GF; Capranzano P; Capodanno D; Tamburino C Int J Cardiol; 2018 Feb; 253():45-49. PubMed ID: 29137819 [TBL] [Abstract][Full Text] [Related]
22. Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention. Allahwala UK; Cockburn JA; Shaw E; Figtree GA; Hansen PS; Bhindi R EuroIntervention; 2015 Feb; 10(10):1154-9. PubMed ID: 24647105 [TBL] [Abstract][Full Text] [Related]
23. Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography. Kraak RP; Kajita AH; Garcia-Garcia HM; Henriques JPS; Piek JJ; Arkenbout EK; van der Schaaf RJ; Tijssen JGP; de Winter RJ; Wykrzykowska JJ Catheter Cardiovasc Interv; 2018 Aug; 92(2):E106-E114. PubMed ID: 29332307 [TBL] [Abstract][Full Text] [Related]
24. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients. Tröbs M; Achenbach S; Röther J; Klinghammer L; Schlundt C Catheter Cardiovasc Interv; 2016 Nov; 88(6):872-880. PubMed ID: 27142643 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436 [TBL] [Abstract][Full Text] [Related]
26. Is high pressure postdilation safe in bioresorbable vascular scaffolds? Optical coherence tomography observations after noncompliant balloons inflated at more than 24 atmospheres. Fabris E; Caiazzo G; Kilic ID; Serdoz R; Secco GG; Sinagra G; Lee R; Foin N; Di Mario C Catheter Cardiovasc Interv; 2016 Apr; 87(5):839-46. PubMed ID: 26370357 [TBL] [Abstract][Full Text] [Related]
27. Bioresorbable vascular scaffolds in coronary chronic total occlusions revascularization: safety assessment related to struts coverage and apposition in 6-month OCT follow-up. Abellas-Sequeiros RA; Ocaranza-Sanchez R; Trillo-Nouche R; Gonzalez-Juanatey C; Gonzalez-Juanatey JR Heart Vessels; 2017 Sep; 32(9):1077-1084. PubMed ID: 28432385 [TBL] [Abstract][Full Text] [Related]
28. Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drug-eluting stents in different degrees of calcification: An Optical Coherence Tomography Study. Ming Fam J; van Der Sijde JN; Karanasos A; Felix C; Diletti R; van Mieghem N; de Jaegere P; Zijlstra F; Jan van Geuns R; Regar E Catheter Cardiovasc Interv; 2017 Apr; 89(5):798-810. PubMed ID: 27717119 [TBL] [Abstract][Full Text] [Related]
29. Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography. Hoppmann P; Rai H; Colleran R; Kufner S; Wiebe J; Cassese S; Joner M; Laugwitz KL; Kastrati A; Byrne RA Cardiovasc Revasc Med; 2020 Mar; 21(3):361-366. PubMed ID: 31231028 [TBL] [Abstract][Full Text] [Related]
31. Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. Wiebe J; Liebetrau C; Dörr O; Most A; Weipert K; Rixe J; Bauer T; Möllmann H; Elsässer A; Hamm CW; Nef HM Int J Cardiol; 2015 Jan; 179():90-4. PubMed ID: 25464422 [TBL] [Abstract][Full Text] [Related]
32. Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea. Kwon O; Ahn JM; Kang DY; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ Korean J Intern Med; 2018 Sep; 33(5):922-932. PubMed ID: 29108400 [TBL] [Abstract][Full Text] [Related]
33. Differential thrombotic prolapse burden in either bioresorbable vascular scaffolds or metallic stents implanted during acute myocardial infarction: The snowshoe effect: Insights from the maximal footprint analysis. Diletti R; van der Sijde J; Karanasos A; Fam JM; Felix C; van Mieghem NM; Regar E; Rapoza R; Zijlstra F; van Geuns RJ Int J Cardiol; 2016 Oct; 220():802-8. PubMed ID: 27394977 [TBL] [Abstract][Full Text] [Related]
34. Routine use of optical coherence tomography in bioresorbable vascular scaffold implantation: insights on technique optimization and long-term outcomes. Abdelaziz HK; Abuomara HZ; Ali MH; Eichhofer J; Patel B; Saad M Coron Artery Dis; 2019 Jun; 30(4):263-269. PubMed ID: 30883433 [TBL] [Abstract][Full Text] [Related]
35. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries). Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443 [TBL] [Abstract][Full Text] [Related]
36. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932 [TBL] [Abstract][Full Text] [Related]